Close

EyePoint Pharmaceuticals (EYPT) Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ CALM Registry Study at ASRS 39th Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. GM
2. SHW
3. SPY
4. AMZN
5. TSLA
6. SPOT
7. NVDA
8. ADBE
9. MTTR
10. CPRI


Go back to EyePoint Pharmaceuticals (EYPT) Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ CALM Registry Study at ASRS 39th Annual Meeting

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting

October 12, 2021 3:00 PM EDT

3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD

YUTIQ® CALM registry study collecting real-world data on patients with fluocinolone acetonide intravitreal (FAi) implant 0.18 mg is ongoing

WATERTOWN, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive interim safety data from its Phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting... More